Agile Therapeutics Company Profile (NASDAQ:AGRX)

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics logoAgile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $96.79 million
  • Outstanding Shares: 28,806,000
Average Prices:
  • 50 Day Moving Avg: $3.27
  • 200 Day Moving Avg: $3.91
  • 52 Week Range: $1.82 - $8.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.94
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.24 per share
  • Price / Book: 2.71
Profitability:
  • EBIDTA: ($29,850,000.00)
  • Return on Equity: -57.50%
  • Return on Assets: -40.30%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 6.55%
  • Quick Ratio: 6.55%
Misc:
  • Average Volume: 275,355 shs.
  • Beta: 2.02
  • Short Ratio: 6.26
 

Frequently Asked Questions for Agile Therapeutics (NASDAQ:AGRX)

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics Inc (NASDAQ:AGRX) released its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.01. View Agile Therapeutics' Earnings History.

Where is Agile Therapeutics' stock going? Where will Agile Therapeutics' stock price be in 2017?

5 equities research analysts have issued 12 month price targets for Agile Therapeutics' shares. Their predictions range from $8.00 to $15.00. On average, they expect Agile Therapeutics' stock price to reach $11.40 in the next year. View Analyst Ratings for Agile Therapeutics.

What are analysts saying about Agile Therapeutics stock?

Here are some recent quotes from research analysts about Agile Therapeutics stock:

  • 1. Cantor Fitzgerald analysts commented, "Undervalued Asset: Following the January results of the Phase 3 SECURE trial, shares have struggled. Following two KOL calls discussed in our April note, however, we continue to believe that AGRX has delivered on what the FDA had previously asked of them following the original CRL and that TWIRLA is an approvable product." (5/8/2017)
  • 2. According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (3/13/2017)

Who are some of Agile Therapeutics' key competitors?

Who owns Agile Therapeutics stock?

Agile Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ProQuest Associates IV LLC (17.57%), Aisling Capital LLC (0.00%), Royce & Associates LP (0.00%), Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%) and Bank of New York Mellon Corp (0.20%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Jay Moorin and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.

Who sold Agile Therapeutics stock? Who is selling Agile Therapeutics stock?

Agile Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Agile Therapeutics.

Who bought Agile Therapeutics stock? Who is buying Agile Therapeutics stock?

Agile Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari, Jay Moorin and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.

How do I buy Agile Therapeutics stock?

Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agile Therapeutics stock cost?

One share of Agile Therapeutics stock can currently be purchased for approximately $3.36.

Analyst Ratings

Consensus Ratings for Agile Therapeutics (NASDAQ:AGRX) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.40 (239.29% upside)

Analysts' Ratings History for Agile Therapeutics (NASDAQ:AGRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Cantor FitzgeraldReiterated RatingBuy$9.00MediumView Rating Details
3/13/2017Noble FinancialReiterated RatingBuyLowView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
1/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/AView Rating Details
1/5/2017Janney Montgomery ScottReiterated RatingBuy$15.00N/AView Rating Details
11/10/2015William BlairReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Agile Therapeutics (NASDAQ:AGRX)
Earnings by Quarter for Agile Therapeutics (NASDAQ:AGRX)
Earnings History by Quarter for Agile Therapeutics (NASDAQ:AGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017Q4 2016($0.28)($0.29)ViewN/AView Earnings Details
11/7/2016Q3($0.35)($0.27)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.38)($0.27)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.42)($0.42)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.37)($0.38)ViewN/AView Earnings Details
5/12/2015Q1 2015($0.35)($0.35)ViewN/AView Earnings Details
3/26/2015Q4 2014($0.40)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.50)($0.34)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agile Therapeutics (NASDAQ:AGRX)
2017 EPS Consensus Estimate: ($1.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.30)($0.30)($0.30)
Q2 20173($0.30)($0.25)($0.28)
Q3 20173($0.31)($0.25)($0.29)
Q4 20173($0.37)($0.26)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agile Therapeutics (NASDAQ:AGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Agile Therapeutics (NASDAQ:AGRX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 83.55%
Insider Trades by Quarter for Agile Therapeutics (NASDAQ:AGRX)
Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)
Insider Trades by Quarter for Agile Therapeutics (NASDAQ:AGRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Alfred AltomariChairmanBuy10,000$3.51$35,100.00View SEC Filing  
5/11/2017Renee SelmanInsiderBuy53,333$3.68$196,265.44View SEC Filing  
1/27/2016Jay MoorinMajor ShareholderBuy393,700$6.35$2,499,995.00View SEC Filing  
6/2/2015Alfred AltomariCEOBuy2,500$8.73$21,825.00View SEC Filing  
1/23/2015Jay MoorinMajor ShareholderBuy811,966$5.85$4,750,001.10View SEC Filing  
5/29/2014Care Capital Iii LlcMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
5/23/2014Andrew N SchiffDirectorBuy1,333,333$6.00$7,999,998.00View SEC Filing  
5/22/2014Ab InvestorMajor ShareholderBuy1,000,000$6.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Agile Therapeutics (NASDAQ:AGRX)
Latest Headlines for Agile Therapeutics (NASDAQ:AGRX)
Source:
DateHeadline
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Forecasted to Post Q2 2017 Earnings of ($0.25) Per Share
www.americanbankingnews.com - May 17 at 8:10 AM
finance.yahoo.com logoAGRX: Initiating Coverage of Agile Therapeutics; NDA for Weekly Contraceptive Patch Set to Be Filed…
finance.yahoo.com - May 15 at 3:24 PM
americanbankingnews.com logoEquities Analysts Set Expectations for Agile Therapeutics Inc's FY2017 Earnings (AGRX)
www.americanbankingnews.com - May 12 at 1:20 PM
americanbankingnews.com logoInsider Buying: Agile Therapeutics Inc (AGRX) Insider Acquires 53,333 Shares of Stock
www.americanbankingnews.com - May 12 at 10:17 AM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Chairman Acquires $35,100.00 in Stock
www.americanbankingnews.com - May 12 at 10:16 AM
americanbankingnews.com logoFY2017 EPS Estimates for Agile Therapeutics Inc (AGRX) Raised by Analyst
www.americanbankingnews.com - May 11 at 11:42 AM
globenewswire.com logoAgile Therapeutics Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 9 at 3:25 PM
rttnews.com logoFDA Snubs TXMD, AGRX To Try Luck Again, CYTK Abuzz, ROKA Surges After-Hours
www.rttnews.com - May 9 at 9:25 AM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Given "Buy" Rating at Cantor Fitzgerald
www.americanbankingnews.com - May 8 at 10:16 PM
finance.yahoo.com logoAgile Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:22 PM
marketbeat.com logoAgile Therapeutics reports 1Q loss
marketbeat.com - May 8 at 5:36 PM
globenewswire.com logoAgile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017 - GlobeNewswire (press release)
globenewswire.com - May 8 at 3:21 PM
rttnews.com logoTXMD All Set For D-day, IMMU Soars On Strategic Plan, CTSO On Watch
www.rttnews.com - May 7 at 3:26 PM
finance.yahoo.com logoAgile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017
finance.yahoo.com - May 6 at 3:52 PM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - May 5 at 8:08 PM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Expected to Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 5 at 6:10 PM
globenewswire.com logoAgile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the ... - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:27 PM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 2 at 10:30 AM
americanbankingnews.com logoAgile Therapeutics (AGRX) Getting Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 9:24 AM
americanbankingnews.com logoAgile Therapeutics (AGRX) Receiving Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 9:01 AM
finance.yahoo.com logoAgile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women's Health - Yahoo Finance
finance.yahoo.com - April 27 at 3:45 PM
finance.yahoo.com logoAgile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
finance.yahoo.com - April 27 at 3:45 PM
americanbankingnews.com logoAgile Therapeutics (AGRX) Earning Somewhat Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 25 at 2:31 PM
americanbankingnews.com logoAgile Therapeutics (AGRX) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 21 at 9:01 AM
americanbankingnews.com logoAgile Therapeutics (AGRX) Earning Somewhat Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 18 at 10:48 AM
americanbankingnews.com logoAgile Therapeutics (AGRX) Getting Somewhat Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 8:53 AM
streetinsider.com logoAgile Therapeutics (AGRX) Says it Has Necessary Info to Complete NDA Resubmission Following FDA Meeting - StreetInsider.com
www.streetinsider.com - April 11 at 8:19 AM
finance.yahoo.com logoAgile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
finance.yahoo.com - April 11 at 8:19 AM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 8 at 7:26 AM
prnewswire.com logoGeneric Drugs Stocks on Investors' Radar -- Diplomat Pharma, Momenta Pharma, Agile Therapeutics, and Sophiris Bio - PR Newswire (press release)
www.prnewswire.com - April 7 at 7:21 AM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - April 4 at 9:48 PM
rttnews.com logoAgile Therapeutics Inc. (AGRX) Has Risen To Nearly A 3-Month High
www.rttnews.com - March 29 at 3:32 PM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Agile Therapeutics Inc's FY2017 Earnings (AGRX)
www.americanbankingnews.com - March 23 at 9:32 AM
finance.yahoo.com logoAGILE THERAPEUTICS INC Financials
finance.yahoo.com - March 21 at 3:48 PM
nasdaq.com logoAgile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
www.nasdaq.com - March 16 at 4:56 PM
biz.yahoo.com logoAGILE THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 16 at 4:56 PM
biz.yahoo.com logoAGILE THERAPEUTICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 15 at 8:37 PM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Earns “Buy” Rating from Noble Financial
www.americanbankingnews.com - March 13 at 10:49 PM
americanbankingnews.com logoAgile Therapeutics Inc Expected to Earn Q1 2017 Earnings of ($0.30) Per Share (AGRX)
www.americanbankingnews.com - March 13 at 11:38 AM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 13 at 10:06 AM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Given a $10.00 Price Target at FBR & Co
www.americanbankingnews.com - March 12 at 9:27 PM
globenewswire.com logoAgile Therapeutics Reports Fourth Quarter and Full Year 2016 ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 3:28 PM
americanbankingnews.com logoAgile Therapeutics Inc (AGRX) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 9 at 12:22 PM
us.rd.yahoo.com logoAgile Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 9 at 1:35 AM
us.rd.yahoo.com logo4:19 pm Agile Therapeutics reports Q4 results, provides corporate update
us.rd.yahoo.com - March 9 at 1:35 AM
biz.yahoo.com logoAGILE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
us.rd.yahoo.com - March 9 at 1:35 AM
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 6:31 AM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) & Lead Plaintiff Deadline - March 7, 2017
finance.yahoo.com - March 6 at 11:16 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 6 at 11:16 AM
globenewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile ... - GlobeNewswire (press release)
globenewswire.com - March 4 at 3:22 PM

Social

Chart

Agile Therapeutics (AGRX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff